Natural Product (NP) Details

General Information of the NP (ID: NP1214)
Name
Wedelolactone
Synonyms
7-Methoxy-5,11,12-trihydroxycoumestan; 7-Methoxy-5,11,12-trihydroxy-coumestan; 1,8,9-Trihydroxy-3-methoxycoumestan; Wedelolactone, Eclipta alba; CHEMBL97453; 0K6L725GNS; CHEBI:10037; IKK Inhibitor II, Wedelolactone; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one; 1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one; 1,8,9-Trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one; AC1NQZ4Z; SCHEMBL601220; GTPL5551; CTK8G3781; DTXSID60200408; Wedelolactone, analyti; 524-12-9; UNII-0K6L725GNS
    Click to Show/Hide
Species Origin Eclipta prostrata ...     Click to Show/Hide
Eclipta prostrata
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Asterales
Family: Asteraceae
Genus: Eclipta
Species: Eclipta prostrata
Disease Keratitis [ICD-11: 9A71] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.947
 
MDCK Permeability
 -4.761
 
PAMPA
 - -
 
HIA
 - - -
 
Distribution
VDss
 -0.486
 
PPB
 94.2%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 +++
CYP1A2 substrate
 - -
CYP2C19 inhibitor
 +++
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 +
CYP2C9 substrate
 ++
CYP2D6 inhibitor
 +++
CYP2D6 substrate
 +++
CYP3A4 inhibitor
 +++
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 ++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +++
 
Excretion
CLplasma
 5.258
 
T1/2
 1.106
Toxicity
DILI
 +++
 
Rat Oral Acute Toxicity
 +
 
FDAMDD
 ++
 
Respiratory
 +
 
Human Hepatotoxicity
 -
 
Ototoxicity
 - -
 
Drug-induced Nephrotoxicity
 - - -
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 - - -
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C16H10O7
PubChem CID
5281813
Canonical SMILES
COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O
InChI
1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3
InChIKey
XQDCKJKKMFWXGB-UHFFFAOYSA-N
CAS Number
CAS 524-12-9
Herb ID
HBIN048224
ETMC ID
7339
SymMap ID
SMIT00178
TCMSP ID
MOL003404
TTD Drug ID
D0F8QJ
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model HeLa CVCL_0030 Endocervical adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)		 Sequential combination of cisplatin with wedelolactone showed synergistic antitumor effect in cervical cancer cells.
Target and Pathway
Target(s) Gamma-aminobutyric acid receptor (GAR)  Molecule Info  [3]
References
Reference 1 Wedelolactone suppresses IL-1Beta maturation and neutrophil infiltration in Aspergillus fumigatus keratitis. Int Immunopharmacol. 2019 Aug;73:17-22.
Reference 2 Synergistic Cytotoxic Effect from Combination of Wedelolactone and Cisplatin in HeLa Cell Line: A Novel Finding. Drug Des Devel Ther. 2020 Sep 22;14:3841-3852.
Reference 3 Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg Med Chem Lett. 2001 Feb 12;11(3):283-6.
 Download Picture         KEGG Link